Catalyst Wire Dossier Catalyst Wire Dossier

Dual-target Chimeric Antigen Receptor T Cells

· Hebei Senlang Biotechnology Inc., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Dual-target Chimeric Antigen Receptor T Cells, covering 2025-06-18 to 2025-06-18. Get the full timeline:

Most recent: Clinical Trial Update: To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors [Phase 1]

See pricing